Roundtable Discussion: Novel Oral Anti-Coagulants (NOACs)
Published: 03 September 2015
-
Views:
853
-
Likes:
7
-
Views:
853
-
Likes:
7
-
18m 22sPart 7 HOW TO CHOOSE BETWEEN NOACS
-
20m 2sPart 1 REAL WORLD VERSUS CLINICAL TRIAL DATA WITH NOACS Paulus Kirchhof, A John Camm, Marco Alings, Raffaele De Caterina, Jean-Yves Le Heuzey, Freek WA Verheugt
-
17m 57sPart 2 ONCE OR TWICE DAILY NOAC THERAPY A John Camm, Paulus Kirchhof, Marco Alings, Raffaele De Caterina, Jean-Yves Le Heuzey, Freek WA Verheugt
-
19m 54sPart 3 SPOT CHECKS OR MONITORING OF NOACS FOR ANTICOAGULATION STATUS Freek WA Verheugt, A John Camm, Marco Alings, Raffaele De Caterina, Paulus Kirchhof, Jean-Yves Le Heuzey
-
19m 54sPart 4 ANTIDOTES FOR NOAC DRUGS A John Camm, Marco Alings, Raffaele De Caterina, Paulus Kirchhof, Jean-Yves Le Heuzey, Freek WA Verheugt
-
20m 37sPart 5 NOACS AND DUAL ANTIPLATELET THERAPY Raffaele De Caterina, A John Camm, Marco Alings, Paulus Kirchhof, Jean-Yves Le Heuzey, Freek WA Verheugt
Overview
On November 12th 2014, Radcliffe Cardiology, in association with the Arrhythmia & Electrophysiology Review (AER) journal, filmed a roundtable discussion entitled 'Novel Oral Anti-Coagulants (NOACs): Hot Topics & Current Issues' in London, UK.
The discussion was moderated by Professor A. John Camm (London, UK), a renowned authority in anticoagulation and atrial fibrillation, and an editorial board member of AER. He was joined by expert group of physicians including Doctor Marco Alings (Breda, NL), Professors Raffaele De Caterina (Chieti, IT), Paulus Kirchhof (Birmingham, UK), Jean-Yves Le Heuzey (Paris, FR) and Freek Verheugt (Amsterdam, NL).
The meeting comprised of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants in various clinical scenarios.
This educational activity is intended for an international audience of non-US healthcare professionals, specifically electrophysiologists and cardiologists. However, neurologists, internal medicine specialists, primary care physicians, and other healthcare professionals involved in the diagnosis and management of patients with atrial fibrillation (AF) will also find this topical.
The CME e-learning modules can be accessed here. This course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 CME credit hour.
On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.
Panellists
- A. John Camm, Professor of Clinical Cardiology and Head of the Department of Cardiac and Vascular Sciences, St. George's Hospital Medical Centre, London, UK
- Marco Alings, Director of the Cardiology Training Program, Amphia Ziekenhuis, Breda, The Netherlands
- Raffaele De Caterina, Professor of Cardiology and Director of the University Cardiology Division, "G. d'Annunzio" University, Chieti, Italy
- Paulus Kirchhof, Chair in Cardiovascular Medicine Cardiovascular and Respiratory Sciences, University of Birmingham, UK
- Jean-Yves Le Heuzey, Professor of Cardiology and Head of the Arrhythmia Department, Georges Pompidou Hospital, Paris, France
- Freek Verheugt, Chairman, Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands
Key Learning Objectives
- To review the established evidence-base for non-VKA thromboprophylaxis in atrial fibrillation (AF)
- o consider recent and emerging data on non-VKA oral anticoagulants in AF trials and registries
- To discuss on-going non-VKA oral anticoagulant research in patients with AF
- To identify and refine the indications for specific non-VKA oral anticoagulants in AF
- To establish the nature of further non-VKA oral anticoagulant research needed for new AF indications
More from this programme
Part 1
SESSION 1
Part 2
SESSION 2
| 1 session | |
| ONCE OR TWICE DAILY NOAC THERAPY | Watch now |
Part 3
SESSION 3
Part 4
SESSION 4
| 1 session | |
| ANTIDOTES FOR NOAC DRUGS | Watch now |
Part 5
SESSION 5
| 1 session | |
| NOACS AND DUAL ANTIPLATELET THERAPY | Watch now |
Part 6
SESSION 6
Part 7
SESSION 7
| 1 session | |
| HOW TO CHOOSE BETWEEN NOACS | Watch now |
Faculty Biographies
A John Camm
Professor of Clinical Cardiology
John Camm is British Heart Foundation Professor of Clinical Cardiology (Emeritus) at St George’s University of London, London, UK. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, and anticoagulation.
Prof Camm is Editor of the European Society of Cardiology Textbook of Cardiovascular Medicine and ESC CardioMed, Electrophysiology of the Heart, Clinical Cardiology and Evidence Based Cardiology. He has written or edited more than 40 books, predominantly in the field of cardiac arrhythmology. He has authored or co-authored more than 1450 peer reviewed papers, more than 500 book chapters, and in excess of 2500 accepted abstracts. He has delivered more than 1000 international lectures.
Prof Camm has been involved in the production of numerous guidelines, including the ESC guidelines for the management of atrial fibrillation.
Prof Camm is a member of the Arrhythmia …
Paulus Kirchhof
Director of the Institute of Cardiovascular Sciences AND Chair in Cardiovascular Medicine
Prof Kirchhof is the Director of the Institute of Cardiovascular Sciences at the University of Birmingham. Prof Kirchhof research includes novel molecular mechanisms of heart disease that can be leveraged to develop personalised treatment approaches to common cardiovascular diseases.
Freek WA Verheugt
Professor of Cardiology and Chairman of the Department of Cardiology